U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959082) titled 'Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer' on April 16.

Brief Summary: This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Head and Neck Cancer Squamous Cell Carcinoma

Intervention: DRUG: VS-101

VS-101

DRUG: Cisplatin

Cisplatin

RADIATION: Radiation

Radiation

Recruitment Status: NOT_YET_RECRUITING

Sponsor: VSPharmTech Co.,Ltd.

Published by HT Digital Content Services with permission from Health Daily Digest....